Adagrasib
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Infobox drug | image = Adagrasib structure.svg | image_class = skin-invert-image | width = | alt = | caption = | pronounce = | tradename = Krazati | Drugs.com = | MedlinePlus = a623003 | DailyMedID = Adagrasib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = XX77 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 2326521-71-3 | CAS_supplemental = | PubChem = 138611145 | IUPHAR_ligand = | DrugBank = DB15568 | ChemSpiderID = | UNII = 8EOO6HQF8Y | KEGG = D12301 | ChEBI = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = MRTX-849 | IUPAC_name = {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1methylpyrrolidin-2-yl]methoxy}-5,6,7,8tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop2-enoyl)piperazin-2-yl}acetonitrile | C=32|H=35|Cl=1|F=1|N=7|O=2 | SMILES = CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=…
{{Infobox drug | image = Adagrasib structure.svg | image_class = skin-invert-image | width = | alt = | caption = | pronounce = | tradename = Krazati | Drugs.com = | MedlinePlus = a623003 | DailyMedID = Adagrasib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = XX77 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 2326521-71-3 | CAS_supplemental = | PubChem = 138611145 | IUPHAR_ligand = | DrugBank = DB15568 | ChemSpiderID = | UNII = 8EOO6HQF8Y | KEGG = D12301 | ChEBI = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = MRTX-849 | IUPAC_name = {(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1methylpyrrolidin-2-yl]methoxy}-5,6,7,8tetrahydropyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop2-enoyl)piperazin-2-yl}acetonitrile | C=32|H=35|Cl=1|F=1|N=7|O=2 | SMILES = CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F | StdInChI = 1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1 | StdInChI_comment = | StdInChIKey = PEMUGDMSUDYLHU-ZEQRLZLVSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer.
Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics. The most common adverse reactions include diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain, and QTc interval prolongation.
Impact
The most common laboratory abnormalities include decreased lymphocytes, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium. It was approved for medical use in the United States in December 2022 for lung cancer and together with cetuximab in 2024 for colorectal cancer.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357077745 under CC BY-SA 4.0; modifications have been made.